Similarly, high FNDC3B expression was associated with lower DSS among PC patients without radiation therapy or primary therapy outcome PR&CR who were male individuals aged ≤ 65 years old with white race and R0 residual tumor status and histologic grade G1 or other anatomic neoplasm subdivisions (Fig. 5J, Q, P < 0.05). The gene discussed is FNDC3B; the disease is neoplasm.